DPCA 2-3_entire_v3

More documents

Recommendations

Info

1 1 Dual Action NovoMix ® 30 2,3 PBS Information: This product is listed on the PBS for the treatment of diabetes mellitus. NOVMIX0065/ADE/FPC Please review Product Information before prescribing. The Product Information can be accessed at www.novonordisk.com.au Minimum Product Information. NovoMix ® 30 (insulin aspart (rys)). Indication: Treatment of diabetes mellitus. Contraindications: Hypoglycaemia. Hypersensitivity to insulin aspart or excipients. Precautions: Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. Where blood glucose is greatly improved, e.g. by intensified insulin therapy, patients may experience a change in usual warning symptoms of hypoglycaemia, and should be advised accordingly. The impact of the rapid onset of action should be considered in patients where a delayed absorption of food might be expected. Do not use in insulin infusion pumps. No studies in children and adolescents under the age of 18. No clinical experience in pregnancy. When thiazolidinediones (TZDs) are used in combination with insulin, patients should be observed for signs and symptoms of congestive heart failure, weight gain and oedema; discontinuation of TZDs may be required. Insulin administration may cause insulin antibodies to form and, in rare cases, may necessitate adjustment of the insulin dose. Interactions: Oral hypoglycaemic agents, octreotide, lanreotide, monoamine oxidase inhibitors, non-selective beta-adrenergic blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids, alpha-adrenergic blocking agents, quinine, quinidine, sulphonamides, oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone, diazoxide, asparaginase, nicotinic acid. Adverse Effects: Hypoglycaemia. Dosage and Administration: Dosage as determined by physician. NovoMix ® 30 should be administered immediately before a meal, or when necessary after the start of a meal. Resuspend immediately before use. Discard the needle after each injection. Subcutaneous injection only. NovoMix ® 30 must not be administered intravenously. (July 2014). References: 1. Liebl A et al. Drugs 2012; 72(11): 1495–520. 2. Wu T et al. Diabetes Ther 2015; 6(3): 273–87. 3. NovoMix ® 30 Approved Product Information (Jul 2014). Novo Nordisk Pharmaceuticals Pty Ltd. ABN 40 002 879 996. Level 3, 21 Solent Circuit, Baulkham Hills, NSW 2153. NovoCare ® Customer Care Centre (Australia) 1800 668 626. www.novonordisk.com.au. ® Registered trademark of Novo Nordisk A/S. AU/NM/0116/0004. January 2016. insulin aspart (rys)
Contents Diabetes & Primary Care Australia Volume 2 No 3 2017 @PCDSAus Website: www.pcdsa.com.au/journal Editorial Our second national conference 85 Rajna Ogrin introduces this issue and reflects on the success of the PCDSA's second national conference. From the other side of the desk I love my CGM: Managing my diabetes is no longer a performance 86 How continuous glucose monitoring helped Tim Burnham get his career back on track. Meeting report 2 nd National Conference of the Primary Care Diabetes Society of Australia 88 Mark Kennedy summarises the sessions from the PCDSA's recent national conference held in Melbourne. CPD module Managing dyslipidaemia in the context of diabetes 100 For this issue’s free education module, Mike Kirby and Roy Rasalam explore the latest thinking on the links between dyslipidaemia and cardiovascular risk, and review the evidence for lipid management in people with diabetes. Articles Sexual health and dysfunction in men and women with diabetes 91 David Edwards and Nicholas Forgione outline the identification and treatment of sexual dysfunction in people with diabetes. Primary care practitioner guide to the International Working Group on the Diabetic Foot: Recommendations for the Australian context 111 Rajna Ogin and Jane Tennant discuss the prevention of diabetes-related foot ulcers and translates international guidelines into the Australian primary care setting. The new class war: SGLT2 inhibitors versus DPP-4 inhibitors 119 Merlin Thomas compares the benefits and risks associated with SGLT2 and DPP-4 inhibitors when added to metformin in type 2 diabetes. Editor-in-Chief Rajna Ogrin Senior Research Fellow, RDNS Institute, St Kilda, Vic Associate Editor Gary Kilov Practice Principal, The Seaport Practice, and Senior Lecturer, University of Tasmania, Launceston, Tas Editorial Board Ralph Audehm GP Director, Dianella Community Health, and Associate Professor, University of Melbourne, Melbourne, Vic Werner Bischof Periodontist, and Associate Professor, LaTrobe University, Bendigo, Vic Anna Chapman Research Fellow, RDNS Institute, St Kilda, Vic Laura Dean Course Director of the Graduate Certificate in Pharmacy Practice, Monash University, Vic Nicholas Forgione Principal, Trigg Health Care Centre, Perth, WA John Furler Principal Research Fellow and Associate Professor, University of Melbourne, Vic Mark Kennedy Medical Director, Northern Bay Health, Geelong, and Honorary Clinical Associate Professor, University of Melbourne, Melbourne, Vic Peter Lazzarini Senior Research Fellow, Queensland University of Technology, Brisbane, Qld Roy Rasalam Head of Clinical Skills and Medical Director, James Cook University, and Clinical Researcher, Townsville Hospital, Townsville, Qld Suzane Ryan Practice Principal, Newcastle Family Practice, Newcastle, NSW Editorial team Olivia Tamburello, Tracy Tran, Charlotte Lindsay Editorial Manager Richard Owen Publisher Simon Breed © OmniaMed SB and the Primary Care Diabetes Society of Australia Published by OmniaMed SB, 1–2 Hatfields, London SE1 9PG, UK All rights reserved. No part of this journal may be reproduced or transmitted in any form, by any means, electronic or mechanic, including photocopying, recording or any information retrieval system, without the publisher’s permission. ISSN 2397-2254 Diabetes & Primary Care Australia Vol 2 No 3 2017 83
Page 1: Diabetes & Primary Care Australia V
Page 5 and 6: Editorial Our second national confe
Page 7 and 8: From the other side of the desk lev
Page 9 and 10: Meeting report Engaging people with
Page 11 and 12: Article Sexual health and dysfuncti
Page 13 and 14: Sexual health and dysfunction in me
Page 19 and 20: Call for papers Would you like to w
Page 21 and 22: CPD module lesions at this stage (R
Page 23 and 24: CPD module and for strokes (Emergin
Page 25 and 26: CPD module in the expectation of a
Page 27 and 28: CPD module levels and a history of
Page 29 and 30: CPD module JBS3 Board (2014) Joint
Page 31 and 32: Article Primary care practitioner g
Page 33 and 34: Primary care practitioner guide to
Page 39 and 40: Article The new class war: SGLT2 in
Page 41 and 42: The new class war Question #4: card
Page 43 and 44: & & & && & & & && & & & && & & & !

DPCA 2-3_entire_v3

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?